BTAI - Why Is Dementia Focused BioXcel Therapeutics Stock Trading Lower Today? | Benzinga
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program of BXCL501 for acute treatment of agitation associated with Alzheimer's dementia.
The company aligned with the FDA's recommendation to conduct an additional Phase 3 trial of BXCL501 to evaluate safety and collect additional efficacy data in at-home setting.
- The planned study is expected to enroll approximately 100 patients aged 65 years and older with mild, moderate, ...